

- 2010;116(18):4334-4344. doi: 10.1002/cncr.25222. PMID: 20549825.
9. Ferrari A, Bono A, Baldi M, et al. Does melanoma behave differently in younger children than in adults? A retrospective study of 33 cases of childhood melanoma from a single institution. *Pediatrics*. 2005;115(3):649-654. doi: 10.1542/peds.2004-0471. PMID: 15741367.
10. Valcayo-Peñalba A, Sánchez-Yus E. El melanoma maligno en menores de quince años (MM sub-15). Un problema poco y mal estudiado. *Actas Dermosifiliogr*. 77.12. 1986: 717-723.
11. Sander B, Karlsson P, Rosdahl I, et al. Cutaneous malignant melanoma in Swedish children and teenagers 1973-1992: a clinico-pathological study of 130 cases. *Int J Cancer*. 1999;80(5): 646-651. doi: 10.1002/(sici)1097-0215(19990301)80:5<646:aid-ijc2>3.0.co;2-h. PMID: 10048960.
12. Mones JM, Ackerman AB. Melanomas in prepubescent children: review comprehensively, critique historically, criteria diagnostically, and course biologically. *Am J Dermatopathol*. 2003;25(3):223-238. doi: 10.1097/00000372-200306000-00007. PMID: 12775985.
13. Spitz S. Melanomas of childhood. *Am J Pathol*. 1948;24: 591-609.
14. Reed RJ, Ichinose H, Clark WH, et al. Common and uncommon melanocytic nevi and borderline melanomas. *Semin Oncol*. 1975;2:119-147.
15. Ruiz-Maldonado R, Orozco-Covarrubias ML. Malignant melanoma in children. A review. *Arch Dermatol*. 1997;133(3): 363-371. Erratum in: *Arch Dermatol* 1997;133(7):833. PMID: 9080898.
17. Sargen MR, Barnhill RL, Elder DE, et al. Evaluation and surgical management of pediatric cutaneous melanoma and atypical spitz and non-spitz melanocytic tumors (melanocytomas): A report from children's oncology group. *J Clin Oncol*. 2024; JCO2401154. doi: 10.1200/JCO.24.01154.
18. Sosnowska-Sienkiewicz P, Januszkiewicz-Lewandowska D, Calik J, et al. Nevi and melanoma in children: What to do in daily medical practice: Encyclopedia for pediatricians and family doctors. *Diagnostics (Basel)*. 2024;14(18). doi: 10.3390/diagnostics14182004.
19. Scoville SD, Stanek JR, Rinehardt H, et al. Comparison of outcomes between surveillance ultrasound and completion lymph node dissection in children and adolescents with sentinel lymph node-positive cutaneous melanoma. *Ann Surg*. 2024;279(3):536-541.
20. Wu YP, Tercyak KP, Wankier AP, et al. Moderating influences on parents' fatalistic beliefs about cancer and their association with sun safety behaviors among children of melanoma survivors: Implications for treatment. *J Health Psychol*. 2024;29(5):481-491.
21. Berg P, Wennberg AM, Tuominen R, et al. Germline CDKN2A mutations are rare in child and adolescent cutaneous melanoma. *Melanoma Res*. 2004;14(4):251-255. doi: 10.1097/01.cmr.0000131014.79262.bf. PMID: 15305154.
22. Leech SN, Bell H, Leonard N, et al. Neonatal giant congenital nevi with proliferative nodules: a clinicopathologic study and literature review of neonatal melanoma. *Arch Dermatol*. 2004;140(1):83-88. doi: 10.1001/archderm.140.1.83. PMID: 14732664.
23. Paradelo S, Fernández-Torres R, Fonseca E. Controversias en el nevus congénito [Controversial issues in congenital nevi]. *Actas Dermosifiliogr*. 2009;100(7):548-561. Spanish. PMID: 19715640.
24. Pampena R, Piccolo V, Muscianese M, et al. Melanoma in children: A systematic review and individual patient meta-analysis. *J Eur Acad Dermatol Venereol*. 2023;37(9):1758-1776. doi: 10.1111/jdv.19220.
25. Jahnke MN, O'Haver J, Gupta D, et al. Care of Congenital Melanocytic Nevi in Newborns and Infants: Review and Management Recommendations. *Pediatrics*. 2021;148(6):e2021051536. doi: 10.1542/peds.2021-051536. PMID: 34845496.
26. Barnhill RL. Pathology of melanocytic nevi and malignant melanoma. Springer Science & Business Media, 2013.
27. Liebmann A, Admard J, Armeanu-Ebinger S, et al. UV-radiation and MC1R germline mutations are risk factors for the development of conventional and spitzoid melanomas in children and adolescents. *EBioMedicine*. 2023;96:104797. doi: 10.1016/j.ebiom.2023.104797. Epub 2023 Sep 14. PMID: 37716236; PMCID: PMC10511785.
28. Kefford RF, Newton Bishop JA, et al. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium. *J Clin Oncol*. 1999;17(10):3245-3251. doi: 10.1200/JCO.1999.17.10.3245. PMID: 10506626.
29. Nakata K, Charvat H. International variations in carcinoma and melanoma incidence in children and adolescents. *Jpn J Clin Oncol*. 2022;52(12):1452-1454. doi: 10.1093/jjco/hyac179.
30. McKenna DB, Doherty VR, McLaren KM, et al. Malignant melanoma and lymphoproliferative malignancy: is there a shared aetiology? *Br J Dermatol*. 2000;143(1):171-173. doi: 10.1046/j.1365-2133.2000.03610.x. PMID: 10886155.
31. Paradelo S, Fonseca E, Pita S, et al. Spitzoid melanoma in children: clinicopathological study and application of immunohistochemistry as an adjunct diagnostic tool. *J Cutan Pathol*. 2009;36(7):740-752. doi: 10.1111/j.1600-0560.2008.01153.x. Epub 2008 Nov 5. PMID: 19032380.
32. Larrosa C, Torrelo A, Madero L, et al. Melanoma in prepubertal children: Diagnostic and therapeutic challenges. *An Pediatr (Engl Ed)*. 2022;96(4):352-357. doi: 10.1016/j.anpede.2021.01.010.
33. Fu YJ, Morota N, Nakagawa A, et al. Neurocutaneous melanosis: surgical pathological features of an apparently hamartomatous lesion in the amygdala. *J Neurosurg Pediatr*. 2010;6(1):82-86. doi: 10.3171/2010.3.PEDS1025. PMID: 20593992.
34. Gargallo P, Yáñez Y, Segura V, et al. Li-Fraumeni syndrome heterogeneity. *Clin Transl Oncol*. 2020;22(7):978-988.
35. Helgadóttir H. Melanoma susceptibility genes in paediatric melanoma and differences in children or adolescents and sporadic or familial cases. *J Eur Acad Dermatol Venereol*. 2022;36(2):167-168. doi: 10.1111/jdv.17879, indexed in PubMed: 35037305.
36. Piccolo V, Moscarella E, Lallas A, et al. MELTUMP: how to manage these lesions in the clinical routine. *G Ital Dermatol Venereol*. 2017;152(3):266-269. doi: 10.23736/50392-0488.17.05569-9. Epub 2017 Feb 14. PMID: 28195450.
37. Herron MD, Vanderhooft SL, Smock K, et al. Proliferative nodules in congenital melanocytic nevi: a clinicopathologic and immunohistochemical analysis. *Am J Surg Pathol*. 2004;28(8):1017-1025. doi: 10.1097/01.pas.0000126785.61609.6e. PMID: 15252307.
38. Ravid JM, Esteves JA. Malignant melanoma of the nose and paranasal sinuses and juvenile melanoma of the nose. *Arch Otolaryngol*. 1960;72:431-444. doi: 10.1001/archotol.1960.00740010441002. PMID: 13739890.
39. Hanchard B, Salmon B. Primary malignant melanoma of the maxillary gingiva in a 4-year-old girl. *West Indian Med J*. 1985;34(4):278-281. PMID: 4090476.
40. Patton EE, Mueller KL, Adams DJ, et al. Melanoma models for the next generation of therapies. *Cancer Cell*. 2021;39(5):610-631. doi: 10.1016/j.ccell.2021.01.011. Epub 2021 Feb 4. PMID: 33545064; PMCID: PMC8378471.
41. Urso C. Spitz Tumors and Melanoma in the Genomic Age: A Retrospective Look at Ackerman's Conundrum. *Cancers (Basel)*. 2023;15(24):5834. doi: 10.3390/cancers15245834. PMID: 38136379; PMCID: PMC10741987.
42. Sandru A, Bordea CI, Voinea SC, et al. Actualități în tratamentul chirurgical al melanomului malign cutanat [Latest approaches in the surgical treatment of cutaneous malignant melanoma]. *Chirurgia (Bucur)*. 2011;106(3):301-308.
43. Pavlick AC. Chemotherapy approaches to melanoma. *Dermatol Clin*. 2002;20(4):709-712. doi: 10.1016/s0733-8635(02)00033-5. PMID: 12380057.
44. Mangana J, Levesque MP, Karpova MB, Dummer R. Sorafenib in melanoma. *Expert Opin Investig Drugs*. 2012;21(4):557-568. doi: 10.1517/13543784.2012.665872. Epub 2012 Mar 7. PMID: 22394203.
45. Guo X, Huang S, Zhang Y, et al. Evodiamine inhibits growth of vemurafenib drug-resistant melanoma via suppressing IRS4/PI3K/AKT signaling pathway. *J Nat Med*. 2024;78(2):342-354. doi: 10.1007/s11418-023-01769-9. Epub 2024 Feb 7. PMID: 38324123.
46. Holzgruber J, Martins C, Kulcsar Z, et al. Type I interferon signaling induces melanoma cell-intrinsic PD-1 and its inhibition antagonizes immune checkpoint blockade. *Nat Commun*. 2024;15(1):7165. doi: 10.1038/s41467-024-51496-2. PMID: 39187481; PMCID: PMC11347607.
47. Smith FO, Downey SG, Klapper JA, et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. *Clin Cancer Res*. 2008;14(17):5610-5618. doi: 10.1158/1078-0432.CCR-08-0116. PMID: 18765555; PMCID: PMC2656367.
48. Hogg D, Monzon JG, Ernst S, et al. Canadian cohort expanded-access program of nivolumab plus ipilimumab in advanced melanoma. *Curr Oncol*. 2020;27(4):204-214. doi: 10.3747/co.27.5985. Epub 2020 Aug 1. PMID: 32905202; PMCID: PMC7467793.
49. Purim KSM, DE-Prá MV, Bahr DC, et al. Survival analysis of children and adolescents with melanoma. *Rev Col Bras Cir*. 2020;47:e20202460. English, Portuguese. doi: 10.1590/0100-6991e-20202460. PMID: 33263650.